Edwards Lifesciences Corp. says data announced last week is poised to calm fears surrounding the approvability of its Sapien transcatheter heart valve when delivered via the transapical route.
Presented Jan. 30 at a late-breaking trial at the Society of Thoracic Surgeons’ annual meeting in Fort Lauderdale, Fla., the data comes from patients given the device via the through-the-ribcage transapical route under the continued access protocol (CAP) section of Edwards’ PARTNER/cohort A U.S
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?